Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions. Issue 2 (4th January 2016)

• Record Type: Journal Article
• Authors: Park, Changhoon; Jeong, Jiwoon; Choi, Kyuhyung; Chae, Chanhee
• Is Part Of: Vaccine. Volume 34:Issue 2(2016)
• Page Start: 270
• Page End: 275
• Publication Date: 2016-01-04
• Subjects: Bivalent vaccine -- Mycoplasma hyopneumoniae -- Porcine circovirus-associated disease -- Porcine circovirus type 2 -- Porcine respiratory disease complex; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.11.034
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: The new bivalent vaccine reduced the levels of PCV2 viremia and mycoplasma nasal shedding. The new bivalent vaccine reduced lung and lymphoid lesions. The new bivalent vaccine protected pigs against either PCV2 or M. hyopneumoniae challenge or both. Abstract: The objective of this study was to evaluate the efficacy of a new bivalent vaccine (Fostera™ PCV MH, Zoetis) of porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae in growing pigs under experimental conditions. A total of 80 pigs were randomly divided into 8 groups (10 pigs per group). The pigs were administered the bivalent vaccine intramuscularly as a 2.0 mL dose at 21 days of age based on the manufacturer's instructions. Three weeks after vaccination, the pigs were inoculated with either PCV2 (intranasal route) or M. hyopneumoniae (intratracheal route) or both. Regardless of the type of inoculation, vaccinated pigs after challenge exhibited effective reduction of clinical signs, PCV2 viremia levels and mycoplasma nasal shedding, and lung and lymphoid lesion when compared to unvaccinated challenged pigs. Vaccinated challenged pigs had significantly higher ( P < 0.05) levels of PCV2-specific neutralizing antibodies, and numbers of PCV2-and M. hyopneumoniae -specific interferon-γ secreting cells compared to unvaccinated challenged pigs. This study demonstrates that the bivalent vaccine is able to protect pigs against either PCV2 or M. hyopneumoniae infection or both based on clinical, microbiological, immunological, and pathological evaluation.